HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference

Stock News

Sep 05

HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.

According to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1118480758"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118480758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118480758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 08:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118480758","market":"nz","top_or_hot":-1,"title":"HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference","media":"Stock News","content":"<p>HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.</p>\n<p>According to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.</p>\n<p>Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-05 08:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.</p>\n<p>According to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.</p>\n<p>Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"","article_id":"1118480758","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118480758","pubTimestamp":1757030911,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","BK1191":"制药","BK4588":"碎股","BK1587":"次新股","BK4585":"ETF&股票定投概念","00013":"和黄医药","BK4007":"制药","HCM":"和黄医药","BK4531":"中概回港概念"},"translate_title":"和黄医药(00013)将于2025年世界肺癌大会暨CSCO 2025年年会展示多项专利化合物研究最新数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.\nAccording to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.\nData from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}